<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304342</url>
  </required_header>
  <id_info>
    <org_study_id>M-17, M-18/21-12-2010</org_study_id>
    <nct_id>NCT01304342</nct_id>
  </id_info>
  <brief_title>Sedation in Endoscopic Retrograde Cholangiopancreatography (ERCP) With or Without Opioids</brief_title>
  <official_title>The Effect of Intranasal Fentanyl Versus Remifentanil Infusion on Propofol Requirements During Elective Therapeutic ERCP, as Well on the Recovery, Pain, and Early Cognitive Function: A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Addition of fentanyl or remifentanil to the propofol produced sedation for scheduled ERCP&#xD;
      will decrease the propofol requirements for predetermined sedation levels (as shown by&#xD;
      Bispectral Index Monitor (BIS) monitor), will be associated with faster recovery monitored by&#xD;
      Ramsay's and Observer's Assessment of Alertness/Sedation (OAAS) scores and BIS, less&#xD;
      postoperative pain (assessed by Visual Analogue Scale=VAS) and less early cognitive&#xD;
      impairment after sedation (as assessed by the MiniMental test).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients After obtaining approval from the Institutional Review Board (IRB) adult patients&#xD;
      ASA I-III aged between 45 and 75 yrs scheduled for elective therapeutic ERCP are enrolled in&#xD;
      the study. All patients are informed and asked to give written informed consent. Those with&#xD;
      chronic pain, consuming opioids or other analgesics, sedatives, hypnotics, allergic to the&#xD;
      drugs to be used in the study protocol, or patients who refuse to give written informed&#xD;
      consent are excluded from the study.&#xD;
&#xD;
      Randomization and blindness Randomization was done by a Research Randomizer program, using 60&#xD;
      sets of numbers and 3 numbers per set for a total of 180 patients, keeping each number in a&#xD;
      set to remain unique and without sorting the numbers that are generated.&#xD;
      (http://www.randomizer.org/). The remifentanil or placebo solutions as well as the nasal&#xD;
      fentanyl or placebo spray are prepared and administered by an independent investigator who is&#xD;
      aware of the group randomization and indicated interventions.&#xD;
&#xD;
      Group 1: Receive remifentanil i.v infusion 1 ml/10 kg/h (10 μg/ml) starting 5 minutes before&#xD;
      propofol administration and continued throughout the procedure. At the same time intranasal&#xD;
      normal saline is given. A bolus dose of propofol 1 mg/kg is followed by propofol infusion and&#xD;
      the infusion is titrated to obtain BIS values around 40-70.&#xD;
&#xD;
      Group 2: Receive normal saline i.v. infusion in volume equal to the volume of remifentanil as&#xD;
      if he/she were assigned to Group 1, intranasal fentanyl 200 μg, and propofol as in group 1.&#xD;
&#xD;
      Group 3: Receive i.v. normal saline infusion in volume equal to the volume of remifentanil as&#xD;
      if he/she were assigned to Group 1, intranasal normal saline, and propofol as in groups 1 and&#xD;
      2.&#xD;
&#xD;
      Anesthetic technique Before opioid/placebo/anesthetic administration all patients receive for&#xD;
      3-5 min 100% oxygen via a face mask from a wall oxygen source by means of a Mapleson C&#xD;
      breathing system. Two venous catheters are inserted in peripheral veins and connected via&#xD;
      extension tubes to two separate infusion pumps for remifentanil or placebo and for propofol&#xD;
      infusion.&#xD;
&#xD;
      Basic monitoring includes pulse oximetry, non-invasive blood pressure (measured in the&#xD;
      beginning and at the end of the procedure), heart rate, respiratory rate and ECG. Additional&#xD;
      monitoring includes BIS, (BIS VIEW ™ Monitoring System, Aspect Medical Systems, Inc. One&#xD;
      Upland Road Norwood, MA 02062 USA). All patients are preoxygenated with 100% oxygen via a&#xD;
      face mask before anesthetic administration. During the procedure oxygen (9 l/min) is&#xD;
      administered via a nasal catheter. Sedation/anesthesia is maintained with propofol bolus 1&#xD;
      mg/kg to begin with, plus infusion (5-9 mg/kg/h) by means of an electric pump to obtain BIS&#xD;
      values around 40-70.&#xD;
&#xD;
      Intraoperative variables to be recorded Baseline values (before starting opioid/placebo) and&#xD;
      every 3 min thereafter throughout the procedure BIS, SpO2, HR, RR, and Movement of the&#xD;
      patient (Yes/No) are recorded and the propofol infusion is increased accordingly. Systolic&#xD;
      and diastolic blood pressure is recorded in the beginning and at the end of the procedure&#xD;
      (not to disturb the patient and change the level of consciousness, except for complications&#xD;
      during the procedure like bleeding, apnea etc). Also events of desaturation (SpO2 below 90),&#xD;
      episodes of apnea (apnea for &gt; than 30s), and other adverse events are recorded. Systolic and&#xD;
      diastolic blood pressure is recorded in the beginning and at the end of the procedure (not to&#xD;
      disturb the patient and change the level of consciousness, except for complications during&#xD;
      the procedure, like bleeding, apnea etc).&#xD;
&#xD;
      At the end of the procedure the total doses of propofol and remifentanil (or the volume of&#xD;
      placebo) are recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Propofol requirements</measure>
    <time_frame>30 min, 60 min and if not full recovery 120 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Speed of recovery</measure>
    <time_frame>30, 60 and 120 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative pain</measure>
    <time_frame>30, 60, and 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>early cognitive function</measure>
    <time_frame>30, 60, and 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>30, 60, and 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endoscopist satisfaction</measure>
    <time_frame>30, 60, and 120 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remifentanil 1 microgram/kg/h along with propofol infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fentanyl 200 micrograms intranasally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline intravenously and intranasally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP</description>
    <arm_group_label>Remifentanil</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Intranasal fentanyl 200 micrograms 5 min before the ERCP</description>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline intravenously and intranasally</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients both sexes&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
          -  aged between 45 and 75 years old&#xD;
&#xD;
          -  scheduled for interventional ERCP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients receiving opioids or other analgesics, sedatives, hypnotics&#xD;
&#xD;
          -  allergic to drugs used in the study protocol&#xD;
&#xD;
          -  alcoholism&#xD;
&#xD;
          -  refuse to sign the informed consent and chronic pain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anesthesiology, Aretaieio Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <last_update_submitted>August 2, 2013</last_update_submitted>
  <last_update_submitted_qc>August 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Argyro Fassoulaki</investigator_full_name>
    <investigator_title>MD, PhD, DEAA</investigator_title>
  </responsible_party>
  <keyword>Propofol</keyword>
  <keyword>remifentanil</keyword>
  <keyword>fentanyl</keyword>
  <keyword>ERCP</keyword>
  <keyword>Quality of sedation</keyword>
  <keyword>recovery</keyword>
  <keyword>satisfaction</keyword>
  <keyword>respiratory depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

